Rho(D) Immune Globulin

Version	Summary	Created by	Modification	Content Size	Created at	Operation
1	handwiki	Vivi Li	--	1930	2022-12-02 01:39:50

The content is sourced from: https://handwiki.org/wiki/Chemistry:Rho(D)_immune_globulin

Rho(D) immune globulin (RhIG) is a medication used to prevent RhD isoimmunization in mothers who are RhD negative and to treat idiopathic thrombocytopenic purpura (ITP) in people who are Rh positive. It is often given both during and following pregnancy. It may also be used when RhD-negative people are given RhD-positive blood. It is given by injection into muscle or a vein. A single dose lasts 12 weeks. Common side effects include fever, headache, pain at the site of injection, and red blood cell breakdown. Other side effects include allergic reactions, kidney problems, and a very small risk of viral infections. In those with ITP, the amount of red blood cell breakdown may be significant. Use is safe with breastfeeding. Rho(D) immune globulin is made up of antibodies to the antigen Rho(D) present on some red blood cells. It is believed to work by blocking a person's immune system from recognizing this antigen. Rho(D) immune globulin came into medical use in the 1960s. It is on the World Health Organization's List of Essential Medicines. It is made from human blood plasma.

immune globulin health red blood cell

References

Committee on Practice Bulletins-Obstetrics (August 2017). "Practice Bulletin No. 181: Prevention of Rh D Alloimmunization.". American Journal of Obstetrics and Gynecology 130 (2): e57–e70. doi:10.1097/AOG.0000000000002232. PMID 28742673. https://dx.doi.org/10.1097%2FAOG.0000000000002232
"Pregnancy - routine anti-D prophylaxis for RhD-negative women". National Institute for Health and Clinical Excellence. May 2002. https://www.nice.org.uk/guidance/TA41/?c=91520.
British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 871. ISBN 9780857111562.
Roback et al. AABB Technical Manual, 16th Ed. Bethesda, AABB Press, 2008.
Bowman JM (1988). "The Prevention of Rh Immunization". Transfus Med Rev 2 (3): 129–50. doi:10.1016/S0887-7963(88)70039-5. PMID 2856526. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1945588
Prevention of Rh D Alloimmunization. ACOG Practice Bulletin Number 4. Washington, DC: American College of Obstetricians and Gynecologists, 1999.
"Use of Anti-D Immunoglobulin for Rh Prophylaxis". Royal College of Obstetricians and Gynaecologists. May 2002. https://www.rcog.org.uk/index.asp?PageID=1972.
Karanth, L; Jaafar, SH; Kanagasabai, S; Nair, NS; Barua, A (Mar 28, 2013). "Anti-D administration after spontaneous miscarriage for preventing Rhesus alloimmunisation.". The Cochrane Database of Systematic Reviews 3 (3): CD009617. doi:10.1002/14651858.CD009617.pub2. PMID 23543581. https://dx.doi.org/10.1002%2F14651858.CD009617.pub2
Bowman JM (1985). "Controversies in Rh Prophylaxis. Who Needs Rh Immune Globulin and When Should it be Given?". Am J Obstet Gynecol 151 (3): 289–94. doi:10.1016/0002-9378(85)90288-1. PMID 2982267. https://dx.doi.org/10.1016%2F0002-9378%2885%2990288-1
Rudmann, Sally V. (2005). Textbook of Blood Banking and Transfusion Medicine 2nd Edition. Elsevier Saunders. pp. 439–441. ISBN 9780721603841. https://books.google.com/books?id=dXdISwJQJFIC&q=%22Textbook+of+Blood+Banking+and+Transfusion+Medicine%22.
Klein Hg and Anstee DJ. Haemolytic Disease of the Fetus and Newborn. In: Mollison's Blood Transfusion in Clinical Medicine. 11th Ed. Oxford: Blackwell, 2005: 496-545.
"International consensus report on the investigation and management of primary immune thrombocytopenia". Blood 115 (2): 168–186. 2010. doi:10.1182/blood-2009-06-225565. PMID 19846889. https://dx.doi.org/10.1182%2Fblood-2009-06-225565
Winrho SDF current prescribing information. Available: www.winrho.com.
"International consensus report on the investigation and management of primary immune thrombocytopenia". Blood 115 (2): 168–186. 2010. doi:10.1182/blood-2009-06-225565. PMID 19846889. https://dx.doi.org/10.1182%2Fblood-2009-06-225565
"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia". Blood 117 (16): 4190–4207. 2011. doi:10.1182/blood-2010-08-302984. PMID 21325604. https://bloodjournal.hematologylibrary.org/content/117/16/4190.full.pdf.
Haspel, Richard L.; Westhoff, Connie M. (March 2015). "How do I manage Rh typing in obstetric patients?: MANAGING OBSTETRIC Rh TYPING". Transfusion 55 (3): 470–474. doi:10.1111/trf.12995. PMID 25647404. https://dx.doi.org/10.1111%2Ftrf.12995
RhoGAM product label, includes clinical trial data and prescribing information https://www2.vaxserve.com/views/PDF/RhoGAM%20Ultra-Filtered%20Plus%20Package%20Insert%207-07.pdf
History of HDN Treatment https://www.rhophylac.com/AboutHDN/evolution.asp
ChromaPlus Manufacturing Process https://www.rhophylac.com/About/chromaplus.asp
RhoGAM Ultra-Filtered PLUS Rho(D) Immune Globulin (Human) Information Site https://www.jnj.com/innovations/new_features/RhoGAM.htm
Staff (5 May 2010). "Cangene assumes U.S. commercialization rights for WinRho SDF". Biotech Week (United States). https://www.highbeam.com/doc/1G1-225162858.html.
Cash, Martin (16 June 2010). "Cangene Corp. begins transformation project". Winnipeg Free Press. https://www.highbeam.com/doc/1P3-2058879031.html.

©Text is available under the terms and conditions of the Creative Commons-Attribution ShareAlike (CC BY-SA) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.

Upload a video for this entry

Information

Subjects: Others

Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :

HandWiki

View Times: 1.0K

Entry Collection: HandWiki

Update Date: 02 Dec 2022

Table of Contents

Video Upload Options

References